Oestrogen receptor-β1 but not oestrogen receptor-βcx is of prognostic value in apocrine carcinoma of the breast
Corresponding Author
NAOKO HONMA
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Department of Breast Pathology, Cancer Institute, Tokyo
Naoko Honma, Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Sakaecho 35-2, Itabashi-ku, Tokyo 173-0015, Japan. e-mail: [email protected]Search for more papers by this authorSHIGEHIRA SAJI
Division of Clinical Trials and Research, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo
Search for more papers by this authorRIE KURABAYASHI
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Search for more papers by this authorJUNKO AIDA
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Search for more papers by this authorTOMIO ARAI
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Search for more papers by this authorRIE HORII
Department of Breast Pathology, Cancer Institute, Tokyo
Search for more papers by this authorFUTOSHI AKIYAMA
Department of Breast Pathology, Cancer Institute, Tokyo
Search for more papers by this authorTAKUJI IWASE
Department of Biochemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Search for more papers by this authorNOBUHIRO HARADA
Department of Pathology, Baylor College of Medicine, Houston, USA
Search for more papers by this authorMAMOUN YOUNES
Department of Breast Oncology, Cancer Institute Hospital, Tokyo
Search for more papers by this authorMASAKAZU TOI
Department of Surgery (Breast Surgery), Graduate School of Medicine Kyoto University, Kyoto, Japan
Search for more papers by this authorKAIYO TAKUBO
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Search for more papers by this authorGOI SAKAMOTO
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Search for more papers by this authorCorresponding Author
NAOKO HONMA
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Department of Breast Pathology, Cancer Institute, Tokyo
Naoko Honma, Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Sakaecho 35-2, Itabashi-ku, Tokyo 173-0015, Japan. e-mail: [email protected]Search for more papers by this authorSHIGEHIRA SAJI
Division of Clinical Trials and Research, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo
Search for more papers by this authorRIE KURABAYASHI
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Search for more papers by this authorJUNKO AIDA
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Search for more papers by this authorTOMIO ARAI
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Search for more papers by this authorRIE HORII
Department of Breast Pathology, Cancer Institute, Tokyo
Search for more papers by this authorFUTOSHI AKIYAMA
Department of Breast Pathology, Cancer Institute, Tokyo
Search for more papers by this authorTAKUJI IWASE
Department of Biochemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Search for more papers by this authorNOBUHIRO HARADA
Department of Pathology, Baylor College of Medicine, Houston, USA
Search for more papers by this authorMAMOUN YOUNES
Department of Breast Oncology, Cancer Institute Hospital, Tokyo
Search for more papers by this authorMASAKAZU TOI
Department of Surgery (Breast Surgery), Graduate School of Medicine Kyoto University, Kyoto, Japan
Search for more papers by this authorKAIYO TAKUBO
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Search for more papers by this authorGOI SAKAMOTO
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo
Search for more papers by this authorReceived 18 March 2008.
Accepted 17 June 2008.
Abstract
Apocrine carcinoma of the breast, which frequently expresses oestrogen receptor-β (ER-β) in the absence of ER-α and only infrequently is treated endocrinologically, gives an opportunity to investigate the clinicopathological role of ER-β in breast cancer independent of ER-α expression or tamoxifen treatment. Several isotypes of ER-β, ER-β1–5 etc., have been identified thus far; however, the clinicopathological importance of each ER-β isotype in breast cancer is still uncertain. Here we aimed to clarify the clinicopathological importance of ER-β1 and ER-βcx (ER-β2) in apocrine carcinomas, immunohistochemically examining expressions of ER-β1 and ER-βcx in 47 apocrine carcinomas. Positivity for ER-β1 and ER-βcx was observed in 41 (87%) and 18 (38%) of 47 cases, respectively. ER-β1 positivity was related to smaller tumor size (P=0.0359), lower histological grade (P=0.0322), and higher disease-free survival (P<0.0001), whereas ER-βcx status was related to none of these parameters. ER-β1 positivity was also associated with favorable clinical outcome in 24 so-called triple-negative (ER-α-negative/PR-negative/HER2-negative) apocrine carcinomas. ER-β1 itself, independent of ER-α expression and tamoxifen treatment, seems to have a tumor-suppressive effect, at least in apocrine carcinomas. Further study of ER-β1 is desired to optimize breast cancer treatment.
REFERENCES
- 1 Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JÅ. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925–30.
- 2 Leygue E, Dotzlaw H, Watson PH, Murphy LC. Expression of estrogen receptor β1, β2, and β5 messenger RNAs in human breast tissue. Cancer Res 1999; 59: 1175–9.
- 3 Speirs V, Parkes AT, Kerin MJ, Walton DS, Carleton PJ, Fox JN, et al. Coexpression of estrogen receptor α and β: poor prognostic factors in human breast cancer? Cancer Res 1999; 59: 525–8.
- 4 Järvinen TAH, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000; 156: 29–35.
- 5 Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 2001; 32: 113–8.
- 6 Omoto Y, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, et al. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 2001; 163: 207–12.
- 7 Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, et al. Expression of estrogen receptor (ER) βcx protein in ERα-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 2002; 62: 4849–53.
- 8 Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V. Evaluation of seven oestrogen receptor β antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 2002; 197: 155–62.
- 9 Speirs V. Oestrogen receptor β in breast cancer: good, bad or still too early to tell? J Pathol 2002; 197: 143–7.
- 10 Fuqua SAW, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne K, et al. Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 2003; 63: 2434–9.
- 11 Balfe P, McCann A, McGoldrick A, McAllister K, Kennedy M, Dervan P, et al. Estrogen receptor alpha and beta profiling in human breast cancer. Eur J Surg Oncol 2004; 30: 469–74.
- 12 Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, et al. The favourable prognostic value of oestrogen receptor β immunohistochemical expression in breast cancer. J Clin Pathol 2004; 57: 523–8.
- 13 O'Neill PA, Davies MPA, Shaaban AM, Innes H, Torevell A, Sibson DR, et al. Wild-type oestrogen receptor beta (ERβ1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 2004; 91: 1694–702.
- 14 Palmieri C, Lam EW, Mansi J, MacDonald C, Shousha S, Madden P, et al. The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 2004; 10: 2421–8.
- 15 Davies MP, O'Neill PA, Innes H, Sibson DR, Prime W, Holcombe C, et al. Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer. J Mol Endocrinol 2004; 33: 773–82.
- 16 Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MRJ, Hanby AM. Oestrogen receptor β: what it means for patients with breast cancer. Lancet Oncol 2004; 5: 174–81.
- 17 Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor β in breast cancer. Cancer Chemother Pharmacol 2005; 56(Suppl 1)): s21–6.
- 18 Miller WR, Anderson TJ, Dixon JM, Saunders PTK. Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br J Cancer 2006; 94: 1333–8.
- 19 Murphy LC, Watson PH. Is oestrogen receptor-β a predictor of endocrine therapy responsiveness in human breast cancer? Endocrine-Related Cancer 2006; 13: 327–34.
- 20 Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, et al. Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun 1998; 247: 75–8.
- 21 Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of oestrogen action in human. Nucleic Acids Res 1998; 26: 3505–12.
- 22 Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, Gustafsson JÅ. Update on estrogen signaling. FEBS Lett 2003; 546: 17–24.
- 23 Frable WJ, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer 1968; 21: 756–63.
- 24 Azzopardi JG. Problems in breast pathology. Major problems in pathology, vol. 11. London : W.B. Saunders, 1979.
- 25
Tavassoli FA,
Purcell CA,
Bratthauer GL,
Man Y.
Androgen receptor expression along with loss of bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications for therapy.
Breast J
1996; 2: 261–9.
10.1111/j.1524-4741.1996.tb00107.x Google Scholar
- 26 Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract 1997; 193: 753–8.
- 27 Leal C, Henrique R, Monteiro P, Lopes C, Bento MJ, Sousa CP, et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum Pathol 2001; 32: 487–93.
- 28 Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, et al. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology 2005; 47: 195–201.
- 29 Miller WR, Telford J, Dixon JM, Shivas AA. Androgen metabolism and apocrine differentiation in human breast cancer. Breast Cancer Res Treat 1985; 5: 67–73.
- 30 Honma N, Takubo K, Akiyama F, Kasumi F, Sawabe M, Arai T, et al. Expression of oestrogen receptor-β in apocrine carcinomas of the breast. Histopathology 2007; 50: 425–33.
- 31 Cleator S, Haller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235–44.
- 32 Perou CM, Sørlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747–52.
- 33 Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133–44.
- 34 Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod Pathol 1994; 7: 813–8.
- 35 Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon : IARC Press, 2003.
- 36 Mazoujian G, Pinkus GS, Davis S, Haagensen DE Jr. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 1983; 110: 105–12.
- 37 Castagna M, Nuti M, Squartini F. Mammary cancer antigen recognized by monoclonal antibody B72.3 in apocrine metaplasia of the human breast. Cancer Res 1987; 47: 902–6.
- 38 Honma N, Takubo K, Arai T, Younes M, Kasumi F, Akiyama F, et al. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast. APMIS 2006; 114: 712–9.
- 39 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–10.
- 40 Allred DC, Harvey JM, Berardo M, Clark G. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155–68.
- 41 Skliris GP, Carder PJ, Lansdown MRJ, Speirs V. Immunohistochemical detection of ER-β in breast cancer: towards more detailed receptor profiling? Br J Cancer 2001; 84: 1095–8.
- 42 Palmieri C, Saji S, Sakaguchi H, Cheng G, Sunters A, O'Hare MJ, et al. The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. J Mol Endocrinol 2004; 33: 35–50.
- 43 Roger P, Sahla ME, Mäkelä S, Gustafsson JÅ, Baldet P, Rochefort H. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res 2001; 61: 2537–41.
- 44 Shaaban AM, O'Neill PA, Davies MPA, Sibson R, West CR, Smith PH, et al. Declining estrogen receptor-β expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 2003; 27: 1502–12.
- 45 Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, et al. Reduced expression of oestrogen receptor β in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003; 201: 213–20.
- 46 Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JÅ, Rochefort H. Increased estrogen receptor βcx expression during mammary carcinogenesis. Clin Cancer Res 2005; 11: 3170–4.
- 47 Shaaban AM, Jarvis C, Moore F, West C, Dodson A, Foster CS. Prognostic significance of estrogen receptor beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 2005; 29: 1593–9.
- 48 Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, et al. Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol (in press).
- 49 Kuenen-Boumeester V, Van der Kwast TH, Van Putten WL, Claassen C, Van Ooijen B, Henzen-Logmans SC. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer 1992; 52: 581–4.
- 50 Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993; 170: 31–5.
- 51 Honma N, Takubo K, Sawabe M, Arai T, Akiyama F, Sakamoto G, et al. Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. J Clin Endocrinol Metab 2006; 91: 607–13.
